02 · Clinical Findings
A Swedish registry signal opens an addiction-research question, not a new treatment claim
Swedish records followed the same people on and off treatment, and the two addictions came apart the moment the medicine stopped.
A Swedish registry analysis found that periods of GLP-1 treatment were associated with fewer hospital admissions related to alcohol and substance-use disorders. The association lasted longer for alcohol-related admissions than for broader substance-use admissions after treatment stopped.
The finding matters because metabolic disease and substance-use disorders can overlap, yet hospital records capture only part of either condition. An observed association cannot show that the medicine treated addiction or explain why the pattern differed across substances.
The next proof step is randomized research that measures craving, use, relapse, and outcomes after discontinuation. Until then, the registry signal is a reason to study the question more closely, not a new indication.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit
At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes
Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
Continue reading · Clinical FindingsPeptide News / Clinical FindingsAmong 167,026 people with type 2 diabetes, the GLP-1 alcohol signal lasted six months and then went quietMedical Xpress · Jul 21, 2026 · scroll to read